{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:08:48Z","timestamp":1787162928936,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"34","license":[{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,23]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Triple-negative breast cancer is characterized by a worse prognosis compared with other breast cancer subtypes, especially in the case of pretreated metastatic triple-negative breast cancer (mTNBC). Because of the limited treatment options and suboptimal response rates, there is a pressing need to explore novel treatment protocols.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 48-year-old female patient diagnosed with mTNBC who had not responded to multiple lines of therapy (including surgery, chemotherapy, and radiotherapy) but demonstrated significant efficacy and abscopal effects after enrolling in our clinical trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Triple-negative breast cancer with lung metastases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>The clinical trial combined stereotactic body radiotherapy, immunotherapy, granulocyte-macrophage colony-stimulating factor, and thymosin alpha-1 to treat previously treated metastatic solid cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>This combined treatment regimen implemented in this clinical trial yielded the patient\u2019s notable efficacy, accompanied by abscopal effects. The target lesion and the 3 observed lesions achieved a partial response according to the RECIST v1.1 criteria. reevaluation scans after 2 cycles of immunotherapy indicated a regression rate of \u221278.97% for the target lesion and \u221256.73% for the observed lesions. Hematological indexes were stable, and there was no apparent myelosuppression. Also, the tumor marker CA-199 exhibited a downward trend. During the course of treatment, the patient experienced a grade 2 skin reaction, which improved after receiving antiallergic treatment. No further adverse effects were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>This treatment regimen may offer a promising treatment strategy for patients with mTNBC and other metastatic solid cancers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000039271","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T01:04:43Z","timestamp":1724634283000},"page":"e39271","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["PD-1 inhibitor combined with SBRT, GM-CSF, and thymosin alpha-1 in metastatic breast cancer: A case report and literature review"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8989-3997","authenticated-orcid":false,"given":"Jiamin","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Radiotherapy, The Affiliated Cancer Hospital of Nanjing Medical University and Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China"},{"name":"Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Xuzhou Cancer Hospital, Xuzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, The Affiliated Cancer Hospital of Nanjing Medical University and Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China"},{"name":"Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zong","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, The Affiliated Cancer Hospital of Nanjing Medical University and Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China"},{"name":"Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7314-1002","authenticated-orcid":false,"given":"Xia","family":"He","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, The Affiliated Cancer Hospital of Nanjing Medical University and Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China"},{"name":"Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1634\/theoncologist.2014-0002","article-title":"Measures of outcome in metastatic breast cancer: insights from a real-world scenario.","volume":"19","author":"Bonotto","year":"2014","journal-title":"Oncologist"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer.","volume":"363","author":"Foulkes","year":"2010","journal-title":"N Engl J Med"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3390\/cancers12040916","article-title":"The Landscape of Targeted Therapies in TNBC.","volume":"12","author":"Vagia","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.","volume":"30","author":"Adams","year":"2019","journal-title":"Ann Oncol"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","article-title":"Radiotherapy combined with immunotherapy: the dawn of cancer treatment.","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"901277","DOI":"10.3389\/fimmu.2022.901277","article-title":"GM-CSF: a double-edged sword in cancer immunotherapy.","volume":"13","author":"Kumar","year":"2022","journal-title":"Front Immunol"},{"issue":"15_suppl","key":"R9-20250503","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1200\/JCO.2018.36.15_suppl.4087","article-title":"Phase 2 trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): clinical outcomes and biomarker analyses.","volume":"36","author":"Kelley","year":"2018","journal-title":"J Clin Oncol"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1749-6632.2012.06680.x","article-title":"Thymosin \u03b11 continues to show promise as an enhancer for vaccine response.","volume":"1270","author":"Tuthill","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/14712598.2018.1494717","article-title":"Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy.","volume":"18","author":"Danielli","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"e202000662","DOI":"10.26508\/lsa.202000662","article-title":"Thymosin alpha1 protects from CTLA-4 intestinal immunopathology.","volume":"3","author":"Renga","year":"2020","journal-title":"Life Sci Alliance"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"e1450128","DOI":"10.1080\/2162402X.2018.1450128","article-title":"Stereotactic body radiation therapy and thymosin alpha-1-induced anti-tumor effects in heavily pretreated, metastatic esophageal squamous cell carcinoma patients.","volume":"7","author":"Du","year":"2018","journal-title":"Oncoimmunology"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/cncr.32599","article-title":"A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer.","volume":"126","author":"Ho","year":"2020","journal-title":"Cancer"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3322\/caac.21731","article-title":"Cancer treatment and survivorship statistics, 2022.","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijrobp.2020.04.034","article-title":"Future of radiation and immunotherapy.","volume":"108","author":"Formenti","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","article-title":"Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.","volume":"22","author":"Winer","year":"2021","journal-title":"Lancet Oncol"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.","volume":"32","author":"Emens","year":"2021","journal-title":"Ann Oncol"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade.","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1667\/RR13731.1","article-title":"Defining molecular signature of pro-immunogenic radiotherapy targets in human prostate cancer cells.","volume":"182","author":"Aryankalayil","year":"2014","journal-title":"Radiat Res"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ijc.25429","article-title":"Regulatory T cells in tumor immunity.","volume":"127","author":"Nishikawa","year":"2010","journal-title":"Int J Cancer"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3389\/fonc.2019.00873","article-title":"A reappraisal of thymosin alpha1 in cancer therapy.","volume":"9","author":"Costantini","year":"2019","journal-title":"Front Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039271","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T20:05:34Z","timestamp":1746302734000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,23]]},"references-count":22,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000039271","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,23]]}}}